Publicly available clinical data showed an association between reduced MEGF10 expression and decreased relapse‐free survival in neuroblastoma (Figure 2C), implying that the in vitro growth regulatory effects may reflect clinically relevant biological behavior. Here, MEGF10 is linked to neuroblastoma.